Logo image of AELIS.PA

AELIS FARMA SAS (AELIS.PA) Stock Fundamental Analysis

EPA:AELIS - Euronext Paris - Matif - FR0014007ZB4 - Common Stock - Currency: EUR

1.41  -0.04 (-2.76%)

Fundamental Rating

2

Taking everything into account, AELIS scores 2 out of 10 in our fundamental rating. AELIS was compared to 72 industry peers in the Biotechnology industry. The financial health of AELIS is average, but there are quite some concerns on its profitability. AELIS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AELIS had negative earnings in the past year.
AELIS had a negative operating cash flow in the past year.
In the past 5 years AELIS reported 4 times negative net income.
AELIS had negative operating cash flow in 4 of the past 5 years.
AELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFAELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M

1.2 Ratios

The Return On Assets of AELIS (-17.92%) is better than 63.89% of its industry peers.
AELIS has a Return On Equity of -35.50%. This is comparable to the rest of the industry: AELIS outperforms 58.33% of its industry peers.
Industry RankSector Rank
ROA -17.92%
ROE -35.5%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AELIS.PA Yearly ROA, ROE, ROICAELIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200

1.3 Margins

AELIS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AELIS.PA Yearly Profit, Operating, Gross MarginsAELIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

AELIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for AELIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AELIS.PA Yearly Shares OutstandingAELIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
AELIS.PA Yearly Total Debt VS Total AssetsAELIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

AELIS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AELIS (0.07) is better than 73.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.93%
AELIS.PA Yearly LT Debt VS Equity VS FCFAELIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

AELIS has a Current Ratio of 2.45. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
AELIS has a Current ratio (2.45) which is in line with its industry peers.
AELIS has a Quick Ratio of 2.44. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
AELIS has a Quick ratio of 2.44. This is comparable to the rest of the industry: AELIS outperforms 59.72% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.44
AELIS.PA Yearly Current Assets VS Current LiabilitesAELIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

AELIS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.01%.
The Revenue has grown by 36.00% in the past year. This is a very strong growth!
EPS 1Y (TTM)-29.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.95%
Revenue 1Y (TTM)36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-40.22%

3.2 Future

AELIS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -19.71% yearly.
Based on estimates for the next years, AELIS will show a very negative growth in Revenue. The Revenue will decrease by -38.58% on average per year.
EPS Next Y-30.17%
EPS Next 2Y163.92%
EPS Next 3Y-19.71%
EPS Next 5YN/A
Revenue Next Year-63.24%
Revenue Next 2Y106.07%
Revenue Next 3Y-38.58%
Revenue Next 5YN/A

3.3 Evolution

AELIS.PA Yearly Revenue VS EstimatesAELIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
AELIS.PA Yearly EPS VS EstimatesAELIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 -1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AELIS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 0.48, the valuation of AELIS can be described as very cheap.
AELIS's Price/Forward Earnings ratio is rather cheap when compared to the industry. AELIS is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.10. AELIS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.48
AELIS.PA Price Earnings VS Forward Price EarningsAELIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AELIS.PA Per share dataAELIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

AELIS's earnings are expected to decrease with -19.71% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y163.92%
EPS Next 3Y-19.71%

More info and screens

0

5. Dividend

5.1 Amount

AELIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AELIS FARMA SAS

EPA:AELIS (3/7/2025, 7:00:00 PM)

1.41

-0.04 (-2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.67%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.33M
Analysts82
Price Target9.28 (558.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.48
P/S 2.56
P/FCF N/A
P/OCF N/A
P/B 0.98
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)2.97
Fwd EY210.38%
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0.55
BVpS1.44
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.92%
ROE -35.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.55%
Cap/Sales 2.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.44
Altman-Z N/A
F-Score4
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)279.92%
Cap/Depr(5y)218.98%
Cap/Sales(3y)2.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.95%
EPS Next Y-30.17%
EPS Next 2Y163.92%
EPS Next 3Y-19.71%
EPS Next 5YN/A
Revenue 1Y (TTM)36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-40.22%
Revenue Next Year-63.24%
Revenue Next 2Y106.07%
Revenue Next 3Y-38.58%
Revenue Next 5YN/A
EBIT growth 1Y-21.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-75%
EBIT Next 3Y-35.56%
EBIT Next 5YN/A
FCF growth 1Y5.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.26%
OCF growth 3YN/A
OCF growth 5YN/A